Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse, mehr …
www.guetsel.de/content/36257/novo-nordisk-a-s-trading-in-novo-nordisk-shares-by-board-members-executives-and-associated-persons.html
Cum-Ex, Cum-Cum und vergleichbare Steuer-Betrugssysteme: Schaden dreifach größer als bisher bekannt – mindestens 150 Milliarden Euro
Nach neuen Berechnungen beläuft sich der weltweite Schaden durch Cum-Ex, Cum-Cum und vergleichbare Betrugssysteme auf mindestens 150 Milliarden Euro. Diese Summe ist dreifach größer als bisher bekannt, mehr …
www.guetsel.de/content/30398/cum-ex-cum-cum-und-vergleichbare-steuer-betrugssysteme-schaden-dreifach-groesser-als-bisher-bekannt-mindestens-150-milliarden-euro.html
Novo Nordisk A/S, Share repurchase programme
On 5 November 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Rules”), mehr …
www.guetsel.de/content/34308/novo-nordisk-a-s-share-repurchase-programme.html
Novo Nordisk A/S, Share repurchase programme
This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 3 February 2021, mehr …
www.guetsel.de/content/34754/novo-nordisk-a-s-share-repurchase-programme.html
Novo Nordisk – major shareholder announcement
Novo Nordisk today announced that the company has been notified by BlackRock, Inc. (Blackrock) that Blackrock as of 8 February 2022 holds B shares equal to 5.05% of the entire share capital of Novo Nordisk. The announcement is in accordance with section 30 of the Danish Capital Markets Act, mehr …
www.guetsel.de/content/36829/novo-nordisk-major-shareholder-announcement.html
Novo Nordisk A/S: Share repurchase programme
On 2 February 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Rules”), mehr …
www.guetsel.de/content/37458/novo-nordisk-a-s-share-repurchase-programme.html
Novo Nordisk – major shareholder announcement
Novo Nordisk today announced that the company has been notified by BlackRock, Inc. (Blackrock) that Blackrock as of 8 March 2022 holds B shares equal to below 5% of the entire share capital of Novo Nordisk. The announcement is in accordance with section 30 of the Danish Capital Markets Act, mehr …
www.guetsel.de/content/39024/novo-nordisk-major-shareholder-announcement.html
Novo Nordisk A/S, Share Repurchase Programme
On 3 May 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Rules”), mehr …
www.guetsel.de/content/43106/novo-nordisk-a-s-share-repurchase-programme.html
Novo Nordisk achieves primary objectives of Onwards 1 and 6 trials
Novo Nordisk today announced headline results from the main phases of Onwards 1 (52 weeks) and Onwards 6 (26 weeks) phase 3a trials with once-weekly insulin icodec, mehr …
www.guetsel.de/content/44467/novo-nordisk-achieves-primary-objectives-of-onwards-1-and-6-trials.html
Novo Nordisk—major shareholder announcement
Novo Nordisk today announced that the company has been notified by Black Rock, Inc. (Blackrock) that Blackrock as of 31 May 2022 holds B shares equal to below 5 percent of the entire share capital of Novo Nordisk. The announcement is in accordance with section 30 of the Danish Capital Markets Act, mehr …
www.guetsel.de/content/44672/novo-nordisk-major-shareholder-announcement.html
Once-weekly insulin icodec demonstrates superior reduction in HbA1c
Mehr …
p style="line-height:150%;">www.guetsel.de/content/51554/once-weekly-insulin-icodec-demonstrates-superior-reduction-in-hba1c.html
Novo Nordisk A/S, Share repurchase programme
The execution of Novo Nordisk A/S’ overall share repurchase programme for 2022 of DKK 24 billion continues, mehr …
www.guetsel.de/content/53353/novo-nordisk-a-s-share-repurchase-programme.html
